Liu, Y. et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci. Transl. Med. 13, eabb5191 (2021).
Magré, L. et al. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J. Immunother. Cancer 11, e006290 (2023).
Duan, Z. et al. CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer. Mol. Ther.: Oncol. 32, 200892 (2024).
Liu, L. et al. Engineering sonogenetic EchoBack-CAR T cells. Cell 188, 2621–2636.e20 (2025).
Lu, Y.-C. et al. Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. JCO 35, 3322–3329 (2017).
Hong, D. S. et al. Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors. JCO 38, 102–102 (2020).
Liu, M. et al. MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity. J. Immunother. Cancer 12, e010248 (2024).
Van Norman, G. A. Limitations of animal studies for predicting toxicity in clinical trials. JACC: Basic Transl. Sci. 4, 845–854 (2019).
Atkins, J. T. et al. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. Br. J. Cancer 123, 1496–1501 (2020).
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).
Gu, S. S. et al. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biol. 21, 263 (2020).
Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309–5337 (2021).
Fennema, E., Rivron, N., Rouwkema, J., Van Blitterswijk, C. & De Boer, J. Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol. 31, 108–115 (2013).
Fang, G., Chen, Y., Lu, H. & Jin, D. Advances in spheroids and organoids on a chip. Adv. Funct. Mater. 33, 2215043 (2023).
Zhang, B. & Radisic, M. Organ-on-a-chip devices advance to market. Lab Chip 17, 2395–2420 (2017).
Leung, C. M. A guide to the organ-on-a-chip. Nat. Rev. Methods Primers 2 (2022).
Bar-Ephraim, Y. E., Kretzschmar, K. & Clevers, H. Organoids in immunological research. Nat. Rev. Immunol. 20, 279–293 (2020).
Hofer, M. & Lutolf, M. P. Engineering organoids. Nat. Rev. Mater. 6, 402–420 (2021).
Zhao, Z. et al. Organoids. Nat. Rev. Methods Prim. 2, 94 (2022).
Wagar, L. E. Human immune organoids: a tool to study vaccine responses. Nat. Rev. Immunol. 23, 699–699 (2023).
Polak, R., Zhang, E. T. & Kuo, C. J. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nat. Rev. Cancer 24, 523–539 (2024).
Tang, X.-Y. et al. Human organoids in basic research and clinical applications. Sig Transduct. Target Ther. 7, 168 (2022).
Ingber, D. E. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat. Rev. Genet. 23, 467–491 (2022).
Nakamura, T. & Sato, T. Advancing intestinal organoid technology toward regenerative. Med. Cell. Mol. Gastroenterol. Hepatol. 5, 51–60 (2018).
Huang, R., Gao, F., Yu, L., Chen, H. & Zhu, R. Generation of neural organoids and their application in disease modeling and regenerative medicine. Adv. Sci. 12, e01198 (2025).
Zheng, M., Erice, E., Wang, H., Zhang, L. & Lawrie, C. H. Organoid-on-a-chip (OrgOC): advancing cystic fibrosis research. Mater. Today Bio 34, 102148 (2025).
Zhao, J. et al. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer’s disease patient iPSC-derived cerebral organoids. Nat. Commun. 11, 5540 (2020).
Liu, X. et al. Analogous comparison unravels heightened antiviral defense and boosted viral infection upon immunosuppression in bat organoids. Sig Transduct. Target Ther. 7, 392 (2022).
Li, P. et al. Mpox virus infection and drug treatment modelled in human skin organoids. Nat. Microbiol. 8, 2067–2079 (2023).
Takebe, T. & Wells, J. M. Organoids by design. Science 364, 956–959 (2019).
Zhao, Y. et al. Integrating organoids and organ-on-a-chip devices. Nat. Rev. Bioeng. 2, 588–608 (2024).
Kim, J. M. & Chen, D. S. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann. Oncol. 27, 1492–1504 (2016).
Kim, R., Emi, M. & Tanabe, K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1–14 (2007).
Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751–765.e16 (2018).
TRACERx consortium, T. he et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).
Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209–223 (2022).
Wolf, Y. et al. UVB-induced tumor heterogeneity diminishes immune response in melanoma. Cell 179, 219–235.e21 (2019).
Klempner, S. J. et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence. Oncologist 25, e147–e159 (2020).
Ricciuti, B. et al. Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 8, 1160 (2022).
Wolf, Y. & Samuels, Y. Intratumor heterogeneity and antitumor immunity shape one another bidirectionally. Clin. Cancer Res. 28, 2994–3001 (2022).
Aggarwal, C. et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw. Open 6, e2311181 (2023).
McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661–672 (2021).
Hellmann, M. D. et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33, 843–852.e4 (2018).
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).
Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44–56 (2019).
Terry, S. et al. New insights into the role of EMT in tumor immune escape. Mol. Oncol. 11, 824–846 (2017).
Malagoli Tagliazucchi, G., Wiecek, A. J., Withnell, E. & Secrier, M. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer. Nat. Commun. 14, 789 (2023).
He, R. et al. Progress in the application of immune checkpoint inhibitor-based immunotherapy for targeting different types of colorectal cancer. Front. Oncol. 11, 764618 (2021).
Chowdhury, S. et al. Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors. Br. J. Cancer 131, 1328–1339 (2024).
Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGFβ in the tumour microenvironment. Nat. Rev. Cancer 13, 788–799 (2013).
Karamitopoulou, E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br. J. Cancer 121, 5–14 (2019).
Bear, A. S. et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat. Commun. 12, 4365 (2021).
Fridman, W. H., Pagès, F., Sautès-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
Dijkstra, K. K. et al. Generation of tumor-reactive t cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586–1598.e12 (2018).
Andel, D. et al. Pre-existing subclones determine radioresistance in rectal cancer organoids. Cell Rep. 43, 113735 (2024).
Kratz, J. D. et al. Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity. Sci. Rep. 15, 12072 (2025).
Mai, Z., Lin, Y., Lin, P., Zhao, X. & Cui, L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 15, 307 (2024).
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
Lee, J. C. et al. The liver-immunity nexus and cancer immunotherapy. Clin. Cancer Res 28, 5–12 (2022).
Wang, Q. et al. Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study. Transl. Lung Cancer Res. 12, 312–321 (2023).
Damsky, W. et al. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. J. Immunother. Cancer 7, 153 (2019).
Griss, J. et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019).
Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).
Thorsson, V. et al. The Immune landscape of cancer. Immunity 48, 812–830.e14 (2018).
Boussiotis, V. A. et al. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc. Natl Acad. Sci. USA 90, 11059–11063 (1993).
Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
Yang, Y. et al. CTLA-4 expression by B-1a B cells is essential for immune tolerance. Nat. Commun. 12, 525 (2021).
Jain, R. K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605–622 (2014).
Kabir, A. U., Subramanian, M., Kwon, Y. & Choi, K. Linking tumour angiogenesis and tumour immunity. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-025-01211-z (2025).
Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906 (2009).
Martin, J. D., Seano, G. & Jain, R. K. Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu. Rev. Physiol. 81, 505–534 (2019).
D’Andrea, M. R. et al. Propensity for early metastatic spread in breast cancer: role of tumor vascularization features and tumor immune infiltrate. Cancers 13, 5917 (2021).
Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678–689 (2007).
Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410–414 (2008).
Ene–Obong, A. et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 145, 1121–1132 (2013).
Woods, A. N. et al. Differential expression of homing receptor ligands on tumor-associated vasculature that control CD8 effector t-cell entry. Cancer Immunol. Res. 5, 1062–1073 (2017).
Heldin, C.-H., Rubin, K., Pietras, K. & Östman, A. High interstitial fluid pressure—an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806–813 (2004).
Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
Anczuków, O. et al. Challenges and opportunities for modeling aging and cancer. Cancer Cell 41, 641–645 (2023).
Gal-Oz, S. T. et al. ImmGen report: sexual dimorphism in the immune system transcriptome. Nat. Commun. 10, 4295 (2019).
Márquez, E. J. et al. Sexual-dimorphism in human immune system aging. Nat. Commun. 11, 751 (2020).
Fane, M. & Weeraratna, A. T. How the ageing microenvironment influences tumour progression. Nat. Rev. Cancer 20, 89–106 (2020).
Chen, A. C. Y. et al. The aged tumor microenvironment limits T cell control of cancer. Nat. Immunol. 25, 1033–1045 (2024).
Dolan, M., Libby, K. A., Ringel, A. E., Van Galen, P. & McAllister, S. S. Ageing, immune fitness and cancer. Nat. Rev. Cancer 25, 848–872 (2025).
Liu, Z. et al. Immunosenescence: molecular mechanisms and diseases. Sig Transduct. Target Ther. 8, 200 (2023).
Hu, J., Pan, M., Reid, B., Tworoger, S. & Li, B. Quantifiable blood TCR repertoire components associate with immune aging. Nat. Commun. 15, 8171 (2024).
Fransen, F. et al. Aged gut microbiota contributes to systemical inflammaging after transfer to germ-free mice. Front. Immunol. 8, 1385 (2017).
Acerbi, I. et al. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr. Biol. 7, 1120–1134 (2015).
Calhoun, C. et al. Senescent cells contribute to the physiological remodeling of aged lungs. GERONA 71, 153–160 (2016).
Tsukita, Y. et al. Immunotherapy or chemoimmunotherapy in older adults with advanced non–small cell lung cancer. JAMA Oncol. 10, 439 (2024).
Kao, C. et al. Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors. Nat. Commun. 16, 3531 (2025).
Kugel, C. H. et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin. Cancer Res. 24, 5347–5356 (2018).
Hamilton, J. A. G. & Henry, C. J. Aging and immunotherapies: new horizons for the golden ages. Aging Cancer 1, 30–44 (2020).
Johnson, D. B., Sullivan, R. J. & Menzies, A. M. Immune checkpoint inhibitors in challenging populations. Cancer 123, 1904–1911 (2017).
Loizides, S. & Papamichael, D. Considerations and challenges in the management of the older patients with gastric cancer. Cancers 14, 1587 (2022).
Tran Van Hoi, E. et al. Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy. Immun. Ageing 21, 83 (2024).
Day, C.-P., Merlino, G. & Van Dyke, T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell 163, 39–53 (2015).
Rehli, M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol. 23, 375–378 (2002).
Mestas, J. & Hughes, C. C. W. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731–2738 (2004).
Huang, L., Xu, H. & Peng, G. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. Cell Mol. Immunol. 15, 428–437 (2018).
Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H. & Xiong, H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27, 218–224 (2008).
Song, I. J. et al. The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int. J. Cancer 142, 81–91 (2018).
Fischer, M. Mice are not humans: the case of p53. Trends Cancer 7, 12–14 (2021).
Frank, M. L. et al. T-cell receptor repertoire sequencing in the era of cancer immunotherapy. Clin. Cancer Res. 29, 994–1008 (2023).
Zomer, H. D. & Trentin, A. G. Skin wound healing in humans and mice: challenges in translational research. J. Dermatol. Sci. 90, 3–12 (2018).
Allison, J. P. & Havran, W. L. The immunobiology of T cells with invariant gammadelta antigen receptors. Annu. Rev. Immunol. 9, 679–705 (1991).
Kupper, T. S. & Fuhlbrigge, R. C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4, 211–222 (2004).
Nagao, K. et al. Stress-induced production of chemokines by hair follicles regulates the trafficking of dendritic cells in skin. Nat. Immunol. 13, 744–752 (2012).
Pasparakis, M., Haase, I. & Nestle, F. O. Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 14, 289–301 (2014).
Lewis, S. M., Williams, A. & Eisenbarth, S. C. Structure and function of the immune system in the spleen. Sci. Immunol. 4, eaau6085 (2019).
Sittig, L. J. et al. Genetic background limits generalizability of genotype-phenotype relationships. Neuron 91, 1253–1259 (2016).
Beura, L. K. et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532, 512–516 (2016).
Rosshart, S. P. et al. Laboratory mice born to wild mice have natural microbiota and model human immune responses. Science 365, eaaw4361 (2019).
Ito, R., Takahashi, T., Katano, I. & Ito, M. Current advances in humanized mouse models. Cell Mol. Immunol. 9, 208–214 (2012).
The Complex Trait Consortium The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat. Genet 36, 1133–1137 (2004).
Kitching, A. R. & Ooi, J. D. From bench to pet shop to bedside? The environment and immune function in mice. Kidney Int. 90, 1142–1143 (2016).
Medetgul-Ernar, K. & Davis, M. M. Standing on the shoulders of mice. Immunity 55, 1343–1353 (2022).
Daly, A. C., Prendergast, M. E., Hughes, A. J. & Burdick, J. A. Bioprinting for the Biologist. Cell 184, 18–32 (2021).
Papargyriou, A. et al. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-024-01273-9 (2024).
Cakir, B. et al. Expression of the transcription factor PU.1 induces the generation of microglia-like cells in human cortical organoids. Nat. Commun. 13, 430 (2022).
Ogawa, J., Pao, G. M., Shokhirev, M. N. & Verma, I. M. Glioblastoma model using human cerebral organoids. Cell Rep. 23, 1220–1229 (2018).
Jacob, F. et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 180, 188–204.e22 (2020).
Sachs, N. et al. A Living Biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373–386.e10 (2018).
Dekkers, J. F. et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat. Protoc. 16, 1936–1965 (2021).
Fujii, M. et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18, 827–838 (2016).
Drost, J. et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521, 43–47 (2015).
Steele, N. G. et al. An organoid-based preclinical model of human gastric cancer. Cell. Mol. Gastroenterol. Hepatol. 7, 161–184 (2019).
Shah, S. B. et al. Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas. Nat. Mater. 22, 511–523 (2023).
Lee, S. H. et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 173, 515–528.e17 (2018).
Lee, M. R. et al. Organoid morphology-guided classification for oral cancer reveals prognosis. Cell Rep. Medi. 6, 102129 (2025).
Pawlowski, K. D., Duffy, J. T., Babak, M. V. & Balyasnikova, I. V. Modeling glioblastoma complexity with organoids for personalized treatments. Trends Mol. Med. 29, 282–296 (2023).
Yan, H. H. N. et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell 23, 882–897.e11 (2018).
Wagar, L. E. et al. Modeling human adaptive immune responses with tonsil organoids. Nat. Med. 27, 125–135 (2021).
Zhong, Z. et al. Human immune organoids to decode B cell response in healthy donors and patients with lymphoma. Nat. Mater. 24, 297–311 (2025).
Griffin, K. H. et al. Engineered bone marrow as a clinically relevant ex vivo model for primary bone cancer research and drug screening. Proc. Natl Acad. Sci. USA 120, e2302101120 (2023).
Olijnik, A.-A. et al. Generating human bone marrow organoids for disease modeling and drug discovery. Nat. Protoc. 19, 2117–2146 (2024).
Gee, K. et al. Spleen organoid units generate functional human and mouse tissue-engineered spleen in a murine model. Tissue Eng. Part A 26, 411–418 (2020).
Seet, C. S. et al. Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. Nat. Methods 14, 521–530 (2017).
Recaldin, T. et al. Human organoids with an autologous tissue-resident immune compartment. Nature 633, 165–173 (2024).
Mallajosyula, V. et al. Coupling antigens from multiple subtypes of influenza can broaden antibody and T cell responses. Science 386, 1389–1395 (2024).
Wagoner, Z. W. et al. Systems immunology analysis of human immune organoids identifies host-specific correlates of protection to different influenza vaccines. Cell Stem Cell 32, 529–546.e6 (2025).
Teufel, C. et al. Lymphoid-tissue-on-chip recapitulates human antibody responses in vitro. https://doi.org/10.1101/2025.01.14.632762 (2025).
Morrison, A. I. et al. Integration of lymphatic vasculature to a human lymph node-on-chip enhances physiological immune properties. Mater. Today Bio 35, 102326 (2025).
Li, C. et al. Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants. Proc. Natl Acad. Sci. USA. 120, e2300376120 (2023).
Wan, Z. et al. Organoid-based neutralization assays reveal a distinctive profile of SARS-CoV-2 antibodies and recapitulate the real-world efficacy. Proc. Natl Acad. Sci. USA. 122, e2509616122 (2025).
Jain, I., Singh, A. & García, A. J. Microphysiological Systems of Lymphatics and Immune Organs. Adv. Healthcare Mater. e03201 (2025).
Yuki, K., Cheng, N., Nakano, M. & Kuo, C. J. Organoid models of tumor immunology. Trends Immunol. 41, 652–664 (2020).
Rogoz, A., Reis, B. S., Karssemeijer, R. A. & Mucida, D. A 3-D enteroid-based model to study T-cell and epithelial cell interaction. J. Immunol. Methods 421, 89–95 (2015).
Nozaki, K. et al. Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J. Gastroenterol. 51, 206–213 (2016).
Schreurs, R. R. C. E. et al. Human fetal TNF-α-cytokine-producing CD4+ effector memory T cells promote intestinal development and mediate inflammation early in life. Immunity 50, 462–476.e8 (2019).
Collin De l’Hortet, A. et al. Generation of human fatty livers using custom-engineered induced pluripotent stem cells with modifiable SIRT1 metabolism. Cell Metab. 30, 385–401.e9 (2019).
Skardal, A. et al. Drug compound screening in single and integrated multi-organoid body-on-a-chip systems. Biofabrication 12, 025017 (2020).
Vazquez-Armendariz, A. I. et al. Multilineage murine stem cells generate complex organoids to model distal lung development and disease. EMBO J. 39, e103476 (2020).
Schreurs, R. R. C. E., Baumdick, M. E., Drewniak, A. & Bunders, M. J. In vitro co-culture of human intestinal organoids and lamina propria-derived CD4+ T cells. STAR Protoc. 2, 100519 (2021).
Cattaneo, C. M. et al. Tumor organoid–T-cell coculture systems. Nat. Protoc. 15, 15–39 (2020).
Li, K. et al. An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer. Cell Stem Cell 32, 1218–1234.e7 (2025).
Neal, J. T. et al. Organoid modeling of the tumor immune microenvironment. Cell 175, 1972–1988.e16 (2018).
Liu, H. et al. A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02845-z (2025).
Dekkers, J. F. et al. Uncovering the mode of action of engineered T cells in patient cancer organoids. Nat. Biotechnol. 41, 60–69 (2023).
Alieva, M. et al. BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response. Nat. Protoc. 19, 2052–2084 (2024).
Aw, D., Silva, A. B. & Palmer, D. B. Immunosenescence: emerging challenges for an ageing population. Immunology 120, 435–446 (2007).
Hossain, M. K., Kim, H.-R. & Chae, H. J. Aging phenotype in AD brain organoids: Track to success and challenges. Ageing Res. Rev. 96, 102256 (2024).
Ao, Z. et al. Understanding immune-driven brain aging by human brain organoid microphysiological analysis platform. Adv. Sci. 9, 2200475 (2022).
Walrath, T. et al. Age-related changes in intestinal immunity and the microbiome. J. Leukoc. Biol. 109, 1045–1061 (2021).
Omrani, O. et al. IFNγ-Stat1 axis drives aging-associated loss of intestinal tissue homeostasis and regeneration. Nat. Commun. 14, 6109 (2023).
Tao, Y. et al. Aging-like spontaneous epigenetic silencing facilitates wnt activation, stemness, and BrafV600E-Induced tumorigenesis. Cancer Cell 35, 315–328.e6 (2019).
Uchida, R. et al. Epigenetic silencing of Lgr5 induces senescence of intestinal epithelial organoids during the process of aging. npj Aging Mech. Dis. 4, 12 (2018).
Nalapareddy, K. et al. Canonical Wnt signaling ameliorates aging of intestinal stem cells. Cell Rep. 18, 2608–2621 (2017).
Kumar, P., Hassan, M., Tacke, F. & Engelmann, C. Delineating the heterogeneity of senescence-induced-functional alterations in hepatocytes. Cell. Mol. Life Sci. 81, 200 (2024).
Torrens-Mas, M. et al. Organoids: an emerging tool to study aging signature across human tissues. modeling aging with patient-derived organoids. IJMS 22, 10547 (2021).
Pitrez, P. R. et al. Cellular reprogramming as a tool to model human aging in a dish. Nat. Commun. 15, 1816 (2024).
Chini, C. C. S. et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat. Metab. 2, 1284–1304 (2020).
Madl, C. M. Accelerating aging with dynamic biomaterials: recapitulating aged tissue phenotypes in engineered platforms. iScience 26, 106825 (2023).
Venkataraman, A. et al. Decoding senescence of aging single cells at the nexus of biomaterials, microfluidics, and spatial omics. npj Aging 10, 57 (2024).
Aguado, J. et al. Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology. Nat. Aging 3, 1561–1575 (2023).
Kong, J. C. H. et al. Tumor-infiltrating lymphocyte function predicts response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. JCO Precision Oncol. 2, 1–15 (2018).
Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).
Jenkins, R. W. et al. Ex vivo profiling of PD-1 Blockade using organotypic tumor spheroids. Cancer Discov. 8, 196–215 (2018).
Scognamiglio, G. et al. Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. Br. J. Cancer 121, 979–982 (2019).
Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 27, 1250–1261 (2021).
Chakrabarti, J. et al. Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget 9, 37439–37457 (2018).
Deng, J. et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 8, 216–233 (2018).
Sun, Y. et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature 615, 158–167 (2023).
Zhou, Z. et al. A T cell-engaging tumor organoid platform for pancreatic cancer immunotherapy. Adv. Sci. 10, 2300548 (2023).
Zhou, R. W. et al. Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. Cell https://doi.org/10.1016/j.cell.2025.09.001 (2025).
Ma, C. et al. Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-025-01428-2 (2025).
Zhang, C. J. et al. A human liver organoid screening platform for DILI risk prediction. J. Hepatol. 78, 998–1006 (2023).
Soussi, F. E. A. et al. Autologous organoid-T cell co-culture platform for modeling of immune-mediated drug-induced liver injury. Adv. Sci. https://doi.org/10.1002/advs.202508584e08584 (2025).
Logun, M. et al. Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell 32, 181–190.e4 (2025).
Kastenschmidt, J. M. et al. Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. Immunity 56, 1910–1926.e7 (2023).
Yin, Q. et al. A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2. Nat. Mater. 22, 380–390 (2023).
Demmers, L. C. et al. Single-cell derived tumor organoids display diversity in HLA class I peptide presentation. Nat. Commun. 11, 5338 (2020).
Dost, A. F. M. et al. Organoids model transcriptional hallmarks of oncogenic KRAS activation in lung epithelial progenitor cells. Cell Stem Cell 27, 663–678.e8 (2020).
Maru, Y. et al. Kras activation in endometrial organoids drives cellular transformation and epithelial-mesenchymal transition. Oncogenesis 10, 46 (2021).
Miura, A. et al. Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression. Int. J. Cancer 149, 1593–1604 (2021).
Toth, A. et al. Alveolar epithelial progenitor cells require Nkx2-1 to maintain progenitor-specific epigenomic state during lung homeostasis and regeneration. Nat. Commun. 14, 8452 (2023).
Reza, H. A. et al. Multi-zonal liver organoids from human pluripotent stem cells. Nature https://doi.org/10.1038/s41586-025-08850-1 (2025).
Frenkel, N. et al. Long-lived human lymphatic endothelial cells to study lymphatic biology and lymphatic vessel/tumor coculture in a 3D microfluidic model. ACS Biomater. Sci. Eng. 7, 3030–3042 (2021).
Votanopoulos, K. I. et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study. Ann. Surg. Oncol. 27, 1956–1967 (2020).
Ronaldson-Bouchard, K. et al. A multi-organ chip with matured tissue niches linked by vascular flow. Nat. Biomed. Eng. 6, 351–371 (2022).
Adu-Berchie, K. et al. Generation of functionally distinct T-cell populations by altering the viscoelasticity of their extracellular matrix. Nat. Biomed. Eng. 7, 1374–1391 (2023).
LeSavage, B. L. et al. Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids. Nat. Mater. 23, 1138–1149 (2024).
Ballerini, M. et al. A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-024-01318-z (2025).
Etesami, N. S. et al. B cells in the pneumococcus-infected lung are heterogeneous and require CD4+ T cell help including CD40L to become resident memory B cells. Front. Immunol. 15, 1382638 (2024).
Lawlor, K. T. et al. Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation. Nat. Mater. 20, 260–271 (2021).
Bliley, J. M., Shiwarski, D. J. & Feinberg, A. W. 3D-bioprinted human tissue and the path toward clinical translation. Sci. Transl. Med. 14, eabo7047 (2022).
Schuster, B. et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat. Commun. 11, 5271 (2020).
Choi, D. et al. Microfluidic organoid cultures derived from pancreatic cancer biopsies for personalized testing of chemotherapy and immunotherapy. Adv. Sci. 11, 2303088 (2024).
Xue, X. et al. Generation of spatially patterned human neural tube-like structures using microfluidic gradient devices. Nat. Protoc. https://doi.org/10.1038/s41596-025-01266-1 (2025).
Lehrich, B. M. et al. Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers. Nat. Commun. 16, 5009 (2025).
Deglincerti, A. et al. Self-organization of human embryonic stem cells on micropatterns. Nat. Protoc. 11, 2223–2232 (2016).
Velasco, V., Shariati, S. A. & Esfandyarpour, R. Microtechnology-based methods for organoid models. Microsyst. Nanoeng. 6, 76 (2020).
Betjes, M. A., Kok, R. N. U., Tans, S. J. & Van Zon, J. S. Cell tracking with accurate error prediction. Nat. Methods https://doi.org/10.1038/s41592-025-02845-6 (2025).
Johnson, J. A. I. et al. Human interpretable grammar encodes multicellular systems biology models to democratize virtual cell laboratories. Cell 188, 4711–4733.e37 (2025).
Kok, R. N. U., Spoelstra, W. K., Betjes, M. A., Van Zon, J. S. & Tans, S. J. Label-free cell imaging and tracking in 3D organoids. Cell Rep. Phys. Sci. 6, 102522 (2025).
Hu, M. et al. SPACE: spatially resolved multiomic analysis for high-throughput CRISPR screening in 3D models. https://doi.org/10.1101/2025.09.14.675819 (2025).
Diosdi, A. et al. HCS-3DX, a next-generation AI-driven automated 3D-oid high-content screening system. Nat. Commun. 16, 8897 (2025).
He, Z. et al. An integrated transcriptomic cell atlas of human neural organoids. Nature 635, 690–698 (2024).
Xu, Q. et al. An integrated transcriptomic cell atlas of human endoderm-derived organoids. Nat. Genet. https://doi.org/10.1038/s41588-025-02182-6 (2025).
Kong, J. et al. Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. Nat. Commun. 11, 5485 (2020).
Kong, J. et al. Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat. Commun. 13, 3703 (2022).
Cai, H. et al. Brain organoid reservoir computing for artificial intelligence. Nat. Electron 6, 1032–1039 (2023).
Bjornson-Hooper, Z. B. et al. A comprehensive atlas of immunological differences between humans, mice, and non-human primates. Front. Immunol. 13, 867015 (2022).
Huminiecki, L. & Wolfe, K. H. Divergence of spatial gene expression profiles following species-specific gene duplications in human and mouse. Genome Res. 14, 1870–1879 (2004).
Liu, T. et al. Cross-species single-cell transcriptomic analysis reveals pre-gastrulation developmental differences among pigs, monkeys, and humans. Cell Discov. 7, 8 (2021).